10x Genomics (TXG) Cash from Financing Activities (2018 - 2026)

10x Genomics has disclosed Cash from Financing Activities across 9 years of filings, most recently posting -$8.4 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$8.4 million, down 2094.55% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.0 million (down 120.99% YoY), and the FY2025 annual result was $6.8 million, down 37.67% from the prior year.
• Cash from Financing Activities came in at -$8.4 million for Q1 2026 at 10x Genomics, down from $2.2 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $7.1 million in Q2 2023 to a low of -$8.4 million in Q1 2026.
• The 5-year median for Cash from Financing Activities is $2.4 million (2022), against an average of $2.3 million.
• Across the five-year window, Cash from Financing Activities jumped 295.51% in 2025 and sank 2094.55% in 2026, its largest moves.
• 10x Genomics' Cash from Financing Activities stood at $5.0 million in 2022, then climbed by 12.24% to $5.6 million in 2023, then dropped by 19.53% to $4.5 million in 2024, then sank by 50.37% to $2.2 million in 2025, then sank by 475.42% to -$8.4 million in 2026.
• The last three Cash from Financing Activities figures came in at -$8.4 million (Q1 2026), $2.2 million (Q4 2025), and $617000.0 (Q3 2025), per Business Quant data.